FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3104092910> ?p ?o ?g. }

• W3104092910 abstract "Acknowledgements This was supported by NCI P01CA069246 (Chiocca) Conclusions Our data suggest that dexamethasone may decrease the efficacy of immunotherapy for glioma through impaired T cell function: this emphasizes the need in identifying alternatives to dexamethasone to prevent attenuated responses in immunotherapies. The combination of GMCI with ATRi however points to additional therapeutic benefit through enhanced cytotoxic efficacy, improved immunogenicity in vitro and increased long-term survival in vivo, making it a promising future approach for the treatment of glioblastoma. Results Cytotoxicity assays showed that dexamethasone has a slight impact on GMCI in vitro. In T-cell-functional assays, we observed a significantly impaired tumor cell killing. Immune cell response assays revealed a reduced immune cell proliferation after co-culture with supernatant from dexamethasone or combination treated glioblastoma cells. In vivo, while treatment with GMCI alone resulted in longer median symptom-free survival (39.5d) versus no treatment (23d), the combination of GMCI and dexamethasone resulted in the significant reduction of this effect (29d vs 39.5d ; p = 0.0184). The combination of ATRi with GMCI proved to be synergistic in cytotoxicity assays. Flow cytometry revealed a significant increase in DSB-associated H2AX foci as well as an improved immune profile by downregulation of GMCI-induced PD-L1 expression. In vivo, the combination with ATRi led to an increase in long-term surviving animals (66.7%) compared to GMCI (50%) and proved to be highly significant compared to the untreated control (p=0.0022). Methods We investigated the effects of ATR-inhibition and dexamethasone on GMCI in vitro using cytotoxicity, flow cytometry and T-cell-killing assays in glioblastoma cell lines. The impact of dexamethasone and ATRi in vivo was assessed in an orthotopic syngeneic murine glioblastoma model. Tumor immune infiltrates were analyzed with flow cytometry. Background Gene-mediated cytotoxic immunotherapy (GMCI) is a local tumor immunotherapy that uses aglatimagene besadenovec (a non-replicating serotype 5 adenovirus, expressing HSV1 thymidine kinase) with the prodrug ganciclovir to induce DNA double strand breaks (DSB), leading to immunogenic tumor cell death and intratumoral immune cell invasion. Here we investigate potential repressors and enhancers of GMCI’s effectiveness. GMCI is currently in clinical trials in combination with immune checkpoint blockade in glioblastoma. Thus we set out to identify potential areas to improve this approach for future application. Dexamethasone is used in symptomatic treatment of glioma patients, although it is known to cause immune suppression. However, the influence of dexamethasone on the efficacy of GMCI has not been explored. In contrast, DNA damage response inhibitors like the ATR inhibitor (ATRi) AZD6738 might not only amend the cytotoxic but also the immunogenic profile of GMCI, rendering it an attractive combination partner." @default.
• W3104092910 created "2020-11-23" @default.
• W3104092910 creator A5002015147 @default.
• W3104092910 creator A5008836248 @default.
• W3104092910 creator A5033917464 @default.
• W3104092910 creator A5041135097 @default.
• W3104092910 creator A5051302499 @default.
• W3104092910 creator A5074040457 @default.
• W3104092910 creator A5080482111 @default.
• W3104092910 creator A5088847670 @default.
• W3104092910 creator A5091648075 @default.
• W3104092910 date "2020-11-01" @default.
• W3104092910 modified "2023-10-18" @default.
• W3104092910 title "468 Enhancers and repressors of immunotherapy: translational perspectives on gene-mediated cytotoxic immunotherapy in glioblastoma" @default.
• W3104092910 cites W2761980878 @default.
• W3104092910 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0468" @default.
• W3104092910 hasPublicationYear "2020" @default.
• W3104092910 type Work @default.
• W3104092910 sameAs 3104092910 @default.
• W3104092910 citedByCount "0" @default.
• W3104092910 crossrefType "journal-article" @default.
• W3104092910 hasAuthorship W3104092910A5002015147 @default.
• W3104092910 hasAuthorship W3104092910A5008836248 @default.
• W3104092910 hasAuthorship W3104092910A5033917464 @default.
• W3104092910 hasAuthorship W3104092910A5041135097 @default.
• W3104092910 hasAuthorship W3104092910A5051302499 @default.
• W3104092910 hasAuthorship W3104092910A5074040457 @default.
• W3104092910 hasAuthorship W3104092910A5080482111 @default.
• W3104092910 hasAuthorship W3104092910A5088847670 @default.
• W3104092910 hasAuthorship W3104092910A5091648075 @default.
• W3104092910 hasConcept C104317684 @default.
• W3104092910 hasConcept C109316439 @default.
• W3104092910 hasConcept C126322002 @default.
• W3104092910 hasConcept C127561419 @default.
• W3104092910 hasConcept C150903083 @default.
• W3104092910 hasConcept C154317977 @default.
• W3104092910 hasConcept C202751555 @default.
• W3104092910 hasConcept C203014093 @default.
• W3104092910 hasConcept C207001950 @default.
• W3104092910 hasConcept C2777701055 @default.
• W3104092910 hasConcept C2778227246 @default.
• W3104092910 hasConcept C2780401358 @default.
• W3104092910 hasConcept C2780868878 @default.
• W3104092910 hasConcept C502942594 @default.
• W3104092910 hasConcept C553184892 @default.
• W3104092910 hasConcept C55493867 @default.
• W3104092910 hasConcept C71924100 @default.
• W3104092910 hasConcept C86803240 @default.
• W3104092910 hasConcept C8891405 @default.
• W3104092910 hasConcept C98274493 @default.
• W3104092910 hasConceptScore W3104092910C104317684 @default.
• W3104092910 hasConceptScore W3104092910C109316439 @default.
• W3104092910 hasConceptScore W3104092910C126322002 @default.
• W3104092910 hasConceptScore W3104092910C127561419 @default.
• W3104092910 hasConceptScore W3104092910C150903083 @default.
• W3104092910 hasConceptScore W3104092910C154317977 @default.
• W3104092910 hasConceptScore W3104092910C202751555 @default.
• W3104092910 hasConceptScore W3104092910C203014093 @default.
• W3104092910 hasConceptScore W3104092910C207001950 @default.
• W3104092910 hasConceptScore W3104092910C2777701055 @default.
• W3104092910 hasConceptScore W3104092910C2778227246 @default.
• W3104092910 hasConceptScore W3104092910C2780401358 @default.
• W3104092910 hasConceptScore W3104092910C2780868878 @default.
• W3104092910 hasConceptScore W3104092910C502942594 @default.
• W3104092910 hasConceptScore W3104092910C553184892 @default.
• W3104092910 hasConceptScore W3104092910C55493867 @default.
• W3104092910 hasConceptScore W3104092910C71924100 @default.
• W3104092910 hasConceptScore W3104092910C86803240 @default.
• W3104092910 hasConceptScore W3104092910C8891405 @default.
• W3104092910 hasConceptScore W3104092910C98274493 @default.
• W3104092910 hasLocation W31040929101 @default.
• W3104092910 hasOpenAccess W3104092910 @default.
• W3104092910 hasPrimaryLocation W31040929101 @default.
• W3104092910 hasRelatedWork W12318454 @default.
• W3104092910 hasRelatedWork W2151330 @default.
• W3104092910 hasRelatedWork W2495403 @default.
• W3104092910 hasRelatedWork W4041773 @default.
• W3104092910 hasRelatedWork W4313372 @default.
• W3104092910 hasRelatedWork W5786864 @default.
• W3104092910 hasRelatedWork W6050890 @default.
• W3104092910 hasRelatedWork W6417289 @default.
• W3104092910 hasRelatedWork W746658 @default.
• W3104092910 hasRelatedWork W8453341 @default.
• W3104092910 isParatext "false" @default.
• W3104092910 isRetracted "false" @default.
• W3104092910 magId "3104092910" @default.
• W3104092910 workType "article" @default.